SG11202001544VA - Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients - Google Patents
Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patientsInfo
- Publication number
- SG11202001544VA SG11202001544VA SG11202001544VA SG11202001544VA SG11202001544VA SG 11202001544V A SG11202001544V A SG 11202001544VA SG 11202001544V A SG11202001544V A SG 11202001544VA SG 11202001544V A SG11202001544V A SG 11202001544VA SG 11202001544V A SG11202001544V A SG 11202001544VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- abnormal bone
- acid sphingomyelinase
- bone conditions
- sphingomyelinase deficiency
- Prior art date
Links
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549732P | 2017-08-24 | 2017-08-24 | |
| EP17306720 | 2017-12-07 | ||
| PCT/IB2018/056346 WO2019038685A2 (en) | 2017-08-24 | 2018-08-22 | Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001544VA true SG11202001544VA (en) | 2020-03-30 |
Family
ID=63556374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001544VA SG11202001544VA (en) | 2017-08-24 | 2018-08-22 | Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11898175B2 (en) |
| EP (1) | EP3672622B1 (en) |
| JP (3) | JP7216075B2 (en) |
| KR (1) | KR20200044064A (en) |
| CN (1) | CN111344003A (en) |
| AU (1) | AU2018319565A1 (en) |
| BR (1) | BR112020003541A2 (en) |
| CA (1) | CA3073648A1 (en) |
| CO (1) | CO2020001801A2 (en) |
| IL (1) | IL272757B1 (en) |
| MX (1) | MX2020002106A (en) |
| PL (1) | PL3672622T3 (en) |
| SG (1) | SG11202001544VA (en) |
| TW (1) | TWI791040B (en) |
| WO (1) | WO2019038685A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38238A (en) * | 2018-05-25 | 2019-12-31 | Genzyme Corp | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY |
| KR20220016103A (en) * | 2019-05-31 | 2022-02-08 | 젠자임 코포레이션 | Two-dimensional LC-MS/MS system |
| CN112773779B (en) * | 2021-02-04 | 2022-08-16 | 上海交通大学医学院附属新华医院 | Application of ambroxol, stephania japonica and hanfang fang in treatment of acid sphingomyelinase deficiency |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| CN1302897A (en) | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | Polypeptide-human phosphodiesterase 21 similar to acidic sphingomyelinase and polynucleotide for coding it |
| US8158582B2 (en) * | 2005-06-02 | 2012-04-17 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-1 deficiency |
| KR20230164773A (en) * | 2009-08-28 | 2023-12-04 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| AU2013225816B2 (en) | 2012-03-02 | 2017-10-26 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Type III Gaucher Disease |
| WO2014093354A1 (en) | 2012-12-12 | 2014-06-19 | Teva Pharmaceutical Industries Ltd. | Fusion of human growth hormone and albumin, formulation and uses thereof |
| MY185990A (en) | 2013-06-07 | 2021-06-14 | Genzyme Corp | Marker for acid sphingomyelinase disorders and uses thereof |
-
2018
- 2018-08-22 MX MX2020002106A patent/MX2020002106A/en unknown
- 2018-08-22 CN CN201880067498.XA patent/CN111344003A/en active Pending
- 2018-08-22 IL IL272757A patent/IL272757B1/en unknown
- 2018-08-22 JP JP2020511325A patent/JP7216075B2/en active Active
- 2018-08-22 TW TW107129257A patent/TWI791040B/en active
- 2018-08-22 CA CA3073648A patent/CA3073648A1/en active Pending
- 2018-08-22 KR KR1020207008213A patent/KR20200044064A/en not_active Application Discontinuation
- 2018-08-22 AU AU2018319565A patent/AU2018319565A1/en active Pending
- 2018-08-22 WO PCT/IB2018/056346 patent/WO2019038685A2/en active Application Filing
- 2018-08-22 SG SG11202001544VA patent/SG11202001544VA/en unknown
- 2018-08-22 PL PL18768948.4T patent/PL3672622T3/en unknown
- 2018-08-22 EP EP18768948.4A patent/EP3672622B1/en active Active
- 2018-08-22 BR BR112020003541-6A patent/BR112020003541A2/en unknown
- 2018-08-22 US US16/641,116 patent/US11898175B2/en active Active
-
2020
- 2020-02-18 CO CONC2020/0001801A patent/CO2020001801A2/en unknown
-
2023
- 2023-01-18 JP JP2023005602A patent/JP7431356B2/en active Active
-
2024
- 2024-01-31 JP JP2024012534A patent/JP2024050732A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020001801A2 (en) | 2020-04-01 |
| CA3073648A1 (en) | 2019-02-28 |
| KR20200044064A (en) | 2020-04-28 |
| EP3672622B1 (en) | 2023-11-08 |
| AU2018319565A1 (en) | 2020-04-09 |
| TWI791040B (en) | 2023-02-01 |
| WO2019038685A2 (en) | 2019-02-28 |
| US20210139868A1 (en) | 2021-05-13 |
| JP2024050732A (en) | 2024-04-10 |
| PL3672622T3 (en) | 2024-04-02 |
| JP7431356B2 (en) | 2024-02-14 |
| MX2020002106A (en) | 2020-07-14 |
| JP2023052459A (en) | 2023-04-11 |
| JP7216075B2 (en) | 2023-01-31 |
| RU2020111649A (en) | 2021-09-24 |
| WO2019038685A3 (en) | 2019-05-02 |
| JP2020531527A (en) | 2020-11-05 |
| BR112020003541A2 (en) | 2020-09-01 |
| TW201919689A (en) | 2019-06-01 |
| IL272757A (en) | 2020-04-30 |
| CN111344003A (en) | 2020-06-26 |
| US11898175B2 (en) | 2024-02-13 |
| IL272757B1 (en) | 2024-03-01 |
| EP3672622A2 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247838A1 (en) | Treatment of bone fractures and defects | |
| EP3680856C0 (en) | Photograph-based assessment of dental treatments and procedures | |
| HK1209623A1 (en) | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders masp-1 / masp-2 / masp-3 | |
| EP3166487A4 (en) | Bone reconstruction and orthopedic implants | |
| IL264301A (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
| HK1250494A1 (en) | Biocompatible implants for nerve re-generation and methods of use thereof | |
| HK1257321A1 (en) | Histotripsy therapy systems and methods for the treatment of brain tissue | |
| IL272757A (en) | Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients | |
| PL3253443T3 (en) | Apparatus for treatment of snoring and sleep apnoea | |
| SG11202000423XA (en) | Treatment of fabry disease in ert-naïve and ert-experienced patients | |
| HK1248756A1 (en) | Lactic acid bacteria and their use for the treatment of mastitis | |
| EP3310282C0 (en) | Implant for the fixation of bone elements | |
| EP3253886A4 (en) | Novel methods for early identification of bone healing ability in injured patients | |
| GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
| IL250662A0 (en) | Tissue protecting devices for treatment of congestive heart failure and other conditions | |
| IL257813A (en) | Combined compositions for controlling blood sugar levels, hepatoprotection, and for prevention and treatment of related medical conditions | |
| GB201503967D0 (en) | Biocompatible implants for use in tendon therapy | |
| EP3518951C0 (en) | Compositions for use in the treatment of osteoporis and bone fractures | |
| IL257935A (en) | Treatment of bone growth disorders | |
| PT3672622T (en) | Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients | |
| GB201403899D0 (en) | Synergistic composition comprising quercetin and polyphosphate for treatment of bone disorders | |
| EP2984999A4 (en) | Locally invasive surgical apparatus comprising manipulator for bone fracture treatment | |
| PL3148468T3 (en) | Apparatus for stimulation and/or treatment of anatomical tissues | |
| PL3182980T3 (en) | Treatment of glycosylation deficiency diseases | |
| IL228155B (en) | Orthopedic implant for treatment of bone deformities |